Small-Cap Catalysts to Watch: April 7 - April 11

We’ve reviewed recent filings and press releases to highlight this week’s key catalysts and upcoming conferences. Stay informed and ahead of the curve!

Companies participating at the 15th Annual LD Micro Invitational Westin Grand Central, New York — April 9–10, 2025

RNXT, CLIR, TBH, FNGR, ELUT, DVLT, INTZ, CJMB, XHLD, INUV, USIO, FRSX, UCL, FEAM, PERF, GAIA, CXDO, ADUR, ALLT

Companies participating at the 24th Annual Needham Virtual Healthcare Conference April 7–10, 2025

OCX, NKTX, CNTX, ADCT, CLSD, DTIL, TCRX, CLYM, PSNL, NSPR, ABSI, CGEN, UNCY, ARTV, MYO, INZY, HOWL, BDTX, VRCA, IMAB, SGHT, ESPR, DCGO, STTK, FGEN, PEPG, AMLX, PIII, OVID, IMRX, LXRX, GBIO, NXTC, KPRX, LUCD, PAVM, BOLD, CATX

Companies participating in the Jones Healthcare and Technology Innovation Conference April 8–9, 2025

CRIS, IMMP, NUVB, OSTX, QNCX, ATYR, EVAX, CLNN, ANIX, CNTX, CALC, VERU, XAIR

Companies participating in the upcoming Water Tower Research Fireside Chat Series April 7–8, 2025

AIMD, SURG, WTI

Companies presenting at the American Academy of Neurology (AAN) 2025 Annual Meeting April 5–9, 2025 – San Diego, CA

ATHE Type: Oral Presentation Title: Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System Atrophy Presenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center Date/Time: Wednesday, April 9, 2025

PMN Title: Novel approach to optimization of Alzheimer's vaccine configuration for maximal targeting of toxic amyloid-beta oligomers Session: P12: Aging, Dementia, and Behavioral Neurology: Alzheimer's treatment Presenter: Johanne Kaplan, Ph.D., Chief Development Officer, ProMIS Neurosciences Date & Time: Wednesday, April 9, 2025

ABOS Title: pTau217 Enrichment Strategy Continues to Reduce Amyloid PET Scans and CSF Testing in Screening (AD/PD Oral Presentation #2813; Encore AAN Oral Presentation #3870)

Companies participating in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum April 8–9, 2025

ENGN, CNTX, CGEN, BDTX, OKUR, CMPX, PYXS, IPHA

Companies attending the 2025 National Association of Broadcasters (NAB) Show April 6–9, 2025 – Las Vegas

VERI, BLZE, BMR, VMEO

Companies participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference April 7, 2025

PPBT, ACET, MRKR, SNSE

Companies presenting at the National Kidney Foundation (NKF) Spring Clinical Meetings April 10–13, 2025

ARDX Title: Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Saw Decreased Stool Frequency and Improved Stool Consistency Authors: Steven Fishbane, Suling Zhao, Susan Edelstein, Yang Yang, David Spiegel Poster Number: G-310 Date/Time: April 10, 2025

AKBA Title: Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD Session: Oral Poster Presentation: Research 3 at NKF SCM25 Presenter: Dr. Wolfgang Winkelmayer Date/Time: Thursday, April 10, 2025 at 4:00 PM

Other companies with key Catalysts this week:

LPTH > Will exhibit at the 2025 Border Security Expo in Phoenix, AZ, on April 8-9, showcasing its expanded infrared imaging solutions from the recent G5 Infrared acquisition and engaging with global security and defense leaders.

VYGR > Will host a live webcast recapping key AD/PD™ 2025 data at 4:30 p.m. ET on Monday, April 7, 2025.

GRO > Management will host a webcast at 4:30 PM ET on Wednesday, April 9, 2025, to provide a business update, including recent developments at the Autazes Potash Project, commercial progress, and strategic objectives for 2025.

MIGI > Mawson CEO and President, Rahul Mewawalla, along with other management team members, will participate in the Google Cloud Next event from April 9-11, 2025.

SHOT > The record date for the spin-off and distribution of Caring Brands, Inc. (CABR) shares is set for April 7, 2025. Stockholders will receive one share of CABR for every 45 shares held as of the record date. The distribution, expected around August 9, 2025, depends on SEC approval and Nasdaq listing. CABR shares are anticipated to begin trading on Nasdaq around April 11, 2025.

VNRX > Will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring key executives Gael Forterre, Dr. Andrew Retter, and Dr. Jake Micallef. The webinar will highlight independent studies supporting the Nu.Q® platform in cancer.

BIVI > Will host a virtual investor event on Thursday, April 10, 2025, at 10:00 AM ET, featuring KOL Dr. Lindsay McAlpine and company management to discuss the long COVID treatment landscape. The event will provide an update on the ADDRESS-LC trial evaluating bezisterim (NE3107) for long COVID, a novel anti-inflammatory agent targeting neuroinflammation.

IMUX > Will attend the AAN 2025 Annual Meeting in San Diego from April 5-9, 2025, at booth #2233. On April 9, 2025, Dr. Hella Kohlhof, CSO of Immunic, will present "Vidofludimus Calcium – Designed to Combine the Best of Two Worlds" at the German Biotech Days in Heidelberg, Germany, during the "All Grown Up?" symposia. The presentation will cover Immunic's lead asset, vidofludimus calcium (IMU-838), and the company's progress.

TPET > Currently holds a 2.25% working interest in 960 acres at Asphalt Ridge and, under the Option, may acquire up to an additional 17.75% working interest in the same 960 acres, along with a 20% interest in an adjacent 1,920 acres. TPET also holds a right of first refusal to participate in approximately 30,000 acres of the greater Asphalt Ridge Project. The Option has been extended, giving TPET until April 10, 2025, to exercise its right to acquire the remaining 17.75% interest in the initial 960 acres.

RAIN > In April 2025, RET will deploy two additional rain generation systems and begin documenting the sourcing, manufacturing, and building process. The company will work on creating a scalable training manual and explore domestic sourcing and U.S.-based manufacturers. RET will also install two systems in its first U.S. location and start software development to automate operations based on local weather, with client reporting on rain generation.

ENTX > The 2025 World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (WCO-IOF-ESCEO) will feature an oral presentation on Friday, April 11, 2025, at 10:00 GMT at the Roma Convention Center, Auditorium A. Additionally, a poster presentation will take place on April 13, 2025.

FTEL > Smart Connected Equipment: Still in development and initiated in May 2021, our smart fitness equipment is a natural extension of our core business and includes interactive exercise bikes and workout mirrors. We expect commercial launch in April 2025.

AAME > The Board of Directors has approved the Company's annual dividend of $0.02 per share. This dividend will be payable on April 23, 2025, to shareholders of record as of April 9, 2025.

INDP > Dr. Roger Waltzman, M.D., M.B.A., Chief Medical Officer, will moderate a panel at the annual CMO360 Summit in Boston on April 7-8, 2025. His panel, titled "Ensuring Effective and Efficient Trials Through Clinical Operations," will take place on Monday, April 7th, from 4:05 PM to 4:35 PM ET.

PBM > Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025.

TORO > In relation to the previously announced spin-off of its wholly owned subsidiary, Robin Energy Ltd. ("Robin"), the record date has been set for April 7, 2025. The distribution of Robin common shares is expected to be completed on or about April 14, 2025. Toro shareholders will receive one common share of Robin for every eight Toro common shares held as of the close of business on the record date.

ORKT > Attending TPAC 2025 from April 6th-8th in Toronto.

MTEK > Will exhibit at the Michigan Defense Expo (MDEX) 2025 from April 8-10, 2025, at the Macomb Sports & Expo Center, Michigan. Alongside SIBAT, the company will showcase its 360° situational awareness technology for Armored Fighting Vehicles and its AI-driven video intelligence and edge computing solutions for defense applications.

SCYX > Four presentations are planned for this year's European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15 2025 in Vienna, Austria.

RGLS > Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9th at 11:32 a.m. ET.

OSTX > The Company will host an Analyst Day at the New York Stock Exchange on April 7, 2025, at 10 am. The focus will be on the OST-HER2 program for osteosarcoma, including its path to Accelerated and conditional approvals in 2025, as well as data in breast cancer and other tumors. The event will also cover assets from Ayala Pharmaceuticals and the potential of its tDC & tADC platforms.

OGI > Organigram Global will host its inaugural virtual investor event, the OG Investor Session, on April 10, 2025, at 4 pm EST. This online event will provide investors with insights into the company's growth, direct engagement with leadership on industry trends, and a behind-the-scenes look at the innovation and strategy shaping Organigram Global's future.

RENB / POAI > Renovaro entered a merger agreement with Predictive Oncology, Inc. ("POI") in January 2025, but POI terminated the transaction on April 3, 2025. Renovaro insists POI must comply with the binding agreements and enter into an exclusive License Agreement. If POI fails to do so by April 10, 2025, Renovaro will seek legal remedies for damages and breaches.

STAI > Will participate and exhibit at the Passenger Terminal Expo 2025, held April 8-10, 2025, at IFEMA, Madrid, Spain. Visit Booth 9226 in Hall 9 to explore the latest innovations in aviation security and passenger experience optimization.

NRSN > Two members of the Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting in San Diego, CA, on April 8, 2025.

QUIK > Exhibiting at the HEART 2025 Conference on April 7th-8th.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.